|
Contents
|
|
|
|
Cancer
Research
|
|
|
|
|
De Rossi A, Rossi L, Laudisi A, Sini V, Toppo L, Marchesi F, Tortorelli G,
Leti M, Turriziani M, Aquino A, Bonmassar E, De Vecchis L, Torino F.
Focus on Fotemustine.
J
Exp Clin Cancer Res. 2006 Dec;25(4):461-8.
.JPG)
Abstract |
.png)
Reprint |
.gif)
Related articles
|
|
|
Fischel JL, Barbé V, Berlion M, Formento P, Berrile J, Bizzari JP, Milano
G.
Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine.
Results on human melanoma cell lines.
Eur
J Cancer. 1993;29A(16):2269-73.
Abstract |
Related articles
|
|
|
Fischel JL, Formento P, Etienne MC, Gioanni J, Frenay M, Deloffre P, Bizzari
JP, Milano G.
In vitro chemosensitivity testing of Fotemustine (S 10036), a new
antitumor nitrosourea.
Cancer
Chemother Pharmacol. 1990;25(5):337-41.
Abstract |
Related articles
|
|
|
Khayat D, Lokiec F, Bizzari JP, Weil M, Meeus L, Sellami M, Rouesse J,
Banzet P, Jacquillat C.
Phase I clinical study of the new amino acid-linked nitrosourea, S 10036,
administered on a weekly schedule.
Cancer Res. 1987 Dec
15;47(24 Pt 1):6782-5.
Abstract |
Reprint |
Related articles
|
|
|
Brain Tumors
|
|
|
|
|
Hargrave DR, Bouffet E, Gammon J, Tariq N, Grant RM, Baruchel S.
Phase I study of fotemustine in pediatric patients with refractory brain
tumors.
Cancer. 2002 Sep 15;95(6):1294-301.
Abstract |
Reprint |
Related articles
|
|
|
Silvani A, Gaviani P,
Lamperti E, Botturi A, Ferrari D, Simonetti G, Salmaggi A.
Lecture: fotemustine in
brain tumors.
Neurol Sci. 2011
Oct 7. [Epub ahead of print]
Abstract |
Reprint |
Related articles
|
|
|
Glioblastoma
|
|
|
|
Laboratory
Investigations |
|
|
|
Ilc K, Ferrero JM, Fischel JL, Formento P, Bryce R,
Etienne MC, Milano G
Cytotoxic
effects of two gamma linoleic salts (lithium gammalinolenate or meglumine
gammalinolenate) alone or associated with a nitrosourea: an experimental study
on human glioblastoma cell lines
Anticancer Drugs
1999 Apr;10(4):413-7
Abstract |
Related articles
|
|
|
Clinical
Investigations |
|
|
|
Newly
Diagnosed Tumors
|
|
|
Altinbas
M, Ozkan M, Er O, Everest H, Coskun SH, Menku A, Cihan Y, Kaplan B.
Adjuvant
radiotherapy and fotemustine in treatment of anaplastic astrocytoma and
glioblastoma multiforme patients.
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No. 459
Abstract
|
|
Fazeny-Dorner
B, Veitl M, Wenzel C, Rossler K, Ungersbock K, Dieckmann K, Piribauer
M, Hainfellner J, Marosi C
Survival
with dacarbazine and fotemustine in newly diagnosed glioblastoma
multiforme
Br J Cancer 2003 Feb 24;88(4):496-501
Abstract |
Reprint |
Related articles
|
|
|
Gallo
C, Buonerba C, Di Lorenzo G, Romeo V, De Placido S, Marinelli A
Can high-dose fotemustine reverse MGMT resistance in glioblastoma
multiforme?
J
Neurooncol.
2010 Nov;100(2):311-9. Epub 2010 Jun 17.
Abstract
|
Reprint |
Related articles
|
|
Recurrent
Tumors
|
|
|
|
Addeo
R, Caraglia M, De Santi MS, Montella L, Abbruzzese A, Parlato C, Vincenzi B,
Carraturo M, Faiola V, Genovese M, Cennamo G, Del Prete S.
A new schedule of fotemustine in temozolomide-pretreated patients with
relapsing glioblastoma
J Neurooncol. 2011 May;102(3):417-24. Epub 2010 Aug 10. Erratum: 2010 Sep 21.
Dosage error in published abstract; MEDLINE/PubMed abstract
corrected.
Abstract |
Reprint
.gif)
Erratum
|
Related
articles
|
|
|
Addeo R, De Santi MS, Del
Prete S, Caraglia M.
Fotemustine
and recurrent glioblastoma: possible new opportunities for an old drug.
Cancer Chemother Pharmacol. 2009 Oct;64(5):863-6. Epub 2009 Jul 29.
Abstract |
Related articles
|
|
Radiotherapy,
Cisplatin, Fotemustine, Temozolomide (Recurrent).
Radiotherapy, Temozolomide (First-diagnosis)
|
Balducci M, Chiesa S,
Diletto B, D'Agostino GR, Mangiola A, Manfrida S, Mantini G, Albanese A,
Fiorentino A, Frascino V, De Bari B, Micciche' F, De Rose F, Morganti AG,
Anile C, Valentini V.
Low-dose fractionated
radiotherapy and concomitant chemotherapy in glioblastoma multiforme with
poor prognosis: a feasibility study.
Neuro Oncol. 2011 Oct
12;. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Brandes
AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M, Amistà P,
Gardiman M, Labianca R, Bianchini C, Ermani M, Reni M
Fotemustine as second-line treatment for recurrent or progressive
glioblastoma after concomitant and/or adjuvant temozolomide: a phase II
trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Cancer Chemother Pharmacol. 2009 Jan 24;. [Epub ahead of print]
Abstract
|
Reprint
|
Related
articles
|
|
|
Fabrini MG, Silvano G, Lolli I, Perrone F, Marsella A, Scotti V, Cionini L
A
multi-institutional phase II study on second-line Fotemustine chemotherapy
in recurrent glioblastoma
J
Neurooncol. 2009 Mar;92(1):79-86. Epub
2008 Nov 19.
Abstract |
Reprint |
Related articles
|
|
|
Fazeny-Dörner B, Veitl M, Wenzel C, Piribauer M, Rössler K, Dieckmann K,
Ungersböck K, Marosi C.
Second-line chemotherapy with dacarbazine and fotemustine in
nitrosourea-pretreated patients with recurrent glioblastoma multiforme.
Anticancer Drugs. 2003
Jul;14(6):437-42.
Abstract |
Related articles
|
|
|
Gaviani P, Salmaggi A, Silvani A.
Combined
chemotherapy with temozolomide and fotemustine in recurrent glioblastoma
patients.
J
Neurooncol. 2011 Jan 13. [Epub ahead of print]
Abstract |
Reprint
|
Related articles
|
|
|
Paccapelo
A, Lolli
I, Scoccianti
S, Detti
B, Silvano
G, Fabrini
MG, Perrone
F, Savio
G, Cascinu
S.
Efficacy of
nitrosourea-based chemotherapy in recurrent malignant glioma according to
time to adjuvant temozolomide failure: A pooled analysis.
ASCO
Meeting Abstracts
Jun
9, 2011:2060
J
Clin Oncol. 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 29, No 15_suppl (May 20 Supplement), 2011:
2060
Abstract
|
|
|
Silvani A, Lamperti E, Gaviani P, Eoli M,
Fiumani A, Salmaggi A, Falcone C, Filippini G, Botturi A, Boiardi A.
Salvage chemotherapy with procarbazine and fotemustine combination in the
treatment of temozolomide treated recurrent glioblastoma patients
J
Neurooncol. 2008 Apr;87(2):143-51. Epub 2007 Jun 19. Erratum in: J
Neurooncol. 2008 Aug;89(1):119. J Neurooncol. 2008 Apr;87(2):153.
Abstract |
Reprint
|
Related articles
|
|
|
Scoccianti S, Detti B,
Sardaro A, Iannalfi A, Meattini I, Leonulli BG, Borghesi S, Martinelli F,
Bordi L, Ammannati F, Biti G.
Second-line
chemotherapy with fotemustine in temozolomide-pretreated patients with
relapsing glioblastoma: a single institution experience.
Anticancer Drugs. 2008
Jul;19(6):613-20.
Abstract |
Related articles
|
|
|
Soffietti R, Trevisan E, Ruda R,
Bertero L, Bosa C, Fabrini MG, Lolli I.
Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma:
Final results of a multicenter study of AINO (Italian Association of
Neuro-oncology).
ASCO Meeting Abstracts Jun 9, 2011:2027.
J Clin Oncol. 2011
ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 29, No 15_suppl
(May 20 Supplement), 2011: 2027
Abstract
|
|
|
Gliomas
|
|
|
|
Clinical
Investigations |
|
|
|
Drug
Interactions
|
|
|
Bourg
V, Lebrun C, Chichmanian RM, Thomas P, Frenay M
Nitroso-urea-cisplatin-based
chemotherapy associated with valproate: increase of haematologic toxicity.
Ann Oncol 2001 Feb;12(2):217-9
Abstract |
Reprint |
Related articles
|
|
Pharmacokinetics
|
|
|
Marzolini
C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T,
Biollaz J, Lejeune F.
Pharmacokinetics
of temozolomide in association with fotemustine in malignant melanoma and
malignant glioma patients: comparison of oral, intravenous, and hepatic
intra-arterial administration.
Cancer
Chemother Pharmacol 1998;42(6):433-40
Abstract |
Erratum
|
Related articles
|
|
Recurrent
Tumors
|
|
|
Boiardi A, Silvani A, Ciusani
E, Watson A, Margison G, Berger E, Lucas C, Giroux B
Fotemustine combined with procarbazine in
recurrent malignant gliomas: a phase I study with evaluation of
lymphocyte 06-alkylguanine-DNA alkyltransferase activity.
J Neurooncol 2001 Apr;52(2):149-56
Abstract |
Reprint |
Related articles
|
|
|
Fabi A, Metro G, Vidiri A, Lanzetta G, Carosi M, Telera S,
Maschio M, Russillo M, Sperduti I, Carapella CM, Cognetti F, Pace A.
Low-dose fotemustine for recurrent malignant glioma: a multicenter phase
II study
J Neurooncol. 2010 Mar 30;. [Epub ahead of print]
Abstract |
Reprint
|
Related
articles
|
|
|
Fabi A, Metro G, Russillo M, Vidiri A, Carapella CM, Maschio M, Cognetti F,
Jandolo B, Mirri MA, Sperduti I, Telera S, Carosi M, Pace A
Treatment
of recurrent malignant gliomas with fotemustine monotherapy: impact of dose
and correlation with MGMT promoter methylation
BMC Cancer. 2009 Mar
31;9:101
Abstract |
Reprint
|
Related
articles
|
|
|
Frenay M, Giroux B, Khoury S, Derlon JM, Namer M.
Phase II study of fotemustine in recurrent supratentorial malignant
gliomas.
Eur
J Cancer. 1991 Jul;27(7):852-6.
Abstract |
Related articles
|
|
|
Khayat D, Giroux B, Berille J, Cour V, Gerard B, Sarkany M, Bertrand P,
Bizzari JP.
Fotemustine in the treatment of brain primary tumors and metastases.
Cancer Invest. 1994
Jan;12(4):414-20.
Abstract |
Related articles
|
|
|
Malhaire JP, Lucas B, Simon H, Person H, Dam-Hieu P, Labat JP.
[Fotemustine (Muphoran) in 22 patients with relapses of high-grade
cerebral gliomas].
Bull Cancer. 1999
Mar;86(3):289-94. French.
Abstract |
.png)
Full
text .gif)
Supplemental
data |
Related articles
|
|
|
Silvani A, Gaviani P,
Lamperti E, Botturi A, Ferrari D, Simonetti G, Salmaggi A.
Lecture: fotemustine in
brain tumors.
Neurol Sci. 2011
Oct 7. [Epub ahead of print]
Abstract |
Related articles
|
|
Depletion
|
|
|
Gander
M, Leyvraz S, Decosterd L, Bonfanti M, Marzolini C, Shen F, Lienard D,
Perey L, Colella G, Biollaz J, Lejeune F, Yarosh D, Belanich M, D'Incalci
M.
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood
lymphocytes and in tumours.
Ann Oncol 1999 Jul;10(7):831-8
Abstract |
Reprint |
Related articles
|
|
|
|
